JP2025131625A5 - - Google Patents
Info
- Publication number
- JP2025131625A5 JP2025131625A5 JP2025083936A JP2025083936A JP2025131625A5 JP 2025131625 A5 JP2025131625 A5 JP 2025131625A5 JP 2025083936 A JP2025083936 A JP 2025083936A JP 2025083936 A JP2025083936 A JP 2025083936A JP 2025131625 A5 JP2025131625 A5 JP 2025131625A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- polymer
- solid dispersion
- amorphous solid
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832606P | 2019-04-11 | 2019-04-11 | |
| US62/832,606 | 2019-04-11 | ||
| PCT/US2020/027677 WO2020210629A1 (en) | 2019-04-11 | 2020-04-10 | Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations |
| JP2021559853A JP2022526656A (ja) | 2019-04-11 | 2020-04-10 | 治療血漿濃度に達するために増強された非晶質固体および溶解製剤の性能 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559853A Division JP2022526656A (ja) | 2019-04-11 | 2020-04-10 | 治療血漿濃度に達するために増強された非晶質固体および溶解製剤の性能 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025131625A JP2025131625A (ja) | 2025-09-09 |
| JP2025131625A5 true JP2025131625A5 (enExample) | 2025-11-07 |
Family
ID=70465560
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559853A Withdrawn JP2022526656A (ja) | 2019-04-11 | 2020-04-10 | 治療血漿濃度に達するために増強された非晶質固体および溶解製剤の性能 |
| JP2025083936A Pending JP2025131625A (ja) | 2019-04-11 | 2025-05-20 | 治療血漿濃度に達するために増強された非晶質固体および溶解製剤の性能 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559853A Withdrawn JP2022526656A (ja) | 2019-04-11 | 2020-04-10 | 治療血漿濃度に達するために増強された非晶質固体および溶解製剤の性能 |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP3953355A1 (enExample) |
| JP (2) | JP2022526656A (enExample) |
| KR (1) | KR20210151183A (enExample) |
| CN (1) | CN113924300A (enExample) |
| AR (1) | AR118650A1 (enExample) |
| AU (1) | AU2020271103A1 (enExample) |
| BR (1) | BR112021020257A2 (enExample) |
| CA (1) | CA3132530A1 (enExample) |
| CL (1) | CL2021002627A1 (enExample) |
| CO (1) | CO2021015054A2 (enExample) |
| EA (1) | EA202192753A1 (enExample) |
| IL (1) | IL287103A (enExample) |
| MX (2) | MX2021012288A (enExample) |
| PE (1) | PE20212367A1 (enExample) |
| SG (1) | SG11202111131VA (enExample) |
| TW (1) | TW202104228A (enExample) |
| WO (1) | WO2020210629A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3212644A1 (en) * | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide |
| JP2024534427A (ja) | 2021-09-17 | 2024-09-20 | ブリストル－マイヤーズ スクイブ カンパニー | 血栓塞栓性障害を予防かつ治療するためのミルベキシアン |
| UY40381A (es) | 2022-08-01 | 2024-01-31 | Janssen Pharmaceutica Nv | Uso de milvexian para el tratamiento o la prevención del accidente cerebrovascular isquémico |
| WO2024167899A1 (en) | 2023-02-06 | 2024-08-15 | Bristol-Myers Squibb Company | Milvexian pharmaceutical compositions |
| WO2025099743A1 (en) * | 2023-11-07 | 2025-05-15 | Dr. Reddy’S Laboratories Limited | Process for preparation of milvexian and solid-state forms thereof |
| WO2025126240A1 (en) * | 2023-12-12 | 2025-06-19 | Dr. Reddy's Laboratories Limited | Pharmaceutical compositions and use thereof |
| WO2025220042A1 (en) * | 2024-04-18 | 2025-10-23 | Dr. Reddy's Laboratories Limited | Pharmaceutical compositions comprising asundexian and use thereof |
| WO2025224678A1 (en) | 2024-04-25 | 2025-10-30 | Assia Chemical Industries Ltd. | Solid state forms of milvexian and process for preparation thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT83812B (en) | 1985-11-27 | 1988-03-15 | Syntex Inc | Process for preparing amorphous benzimidazole derivatives |
| PT901786E (pt) * | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
| WO2010102245A1 (en) | 2009-03-05 | 2010-09-10 | Upsher-Smith Laboratories, Inc. | Solid dispersion comprising resveratrol |
| UY40230A (es) * | 2014-01-31 | 2023-08-15 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Macrociclos con grupos P2’ heterocíclicos como inhibidores del factor XIa y composiciones farmacéuticas que los comprenden |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| NO2721243T3 (enExample) * | 2014-10-01 | 2018-10-20 |
-
2020
- 2020-04-10 KR KR1020217036797A patent/KR20210151183A/ko active Pending
- 2020-04-10 EP EP20722195.3A patent/EP3953355A1/en active Pending
- 2020-04-10 EA EA202192753A patent/EA202192753A1/ru unknown
- 2020-04-10 SG SG11202111131VA patent/SG11202111131VA/en unknown
- 2020-04-10 BR BR112021020257A patent/BR112021020257A2/pt unknown
- 2020-04-10 PE PE2021001691A patent/PE20212367A1/es unknown
- 2020-04-10 WO PCT/US2020/027677 patent/WO2020210629A1/en not_active Ceased
- 2020-04-10 MX MX2021012288A patent/MX2021012288A/es unknown
- 2020-04-10 TW TW109112257A patent/TW202104228A/zh unknown
- 2020-04-10 CA CA3132530A patent/CA3132530A1/en active Pending
- 2020-04-10 AU AU2020271103A patent/AU2020271103A1/en active Pending
- 2020-04-10 CN CN202080041944.7A patent/CN113924300A/zh active Pending
- 2020-04-10 JP JP2021559853A patent/JP2022526656A/ja not_active Withdrawn
- 2020-04-13 AR ARP200101025A patent/AR118650A1/es unknown
-
2021
- 2021-10-07 IL IL287103A patent/IL287103A/en unknown
- 2021-10-07 CL CL2021002627A patent/CL2021002627A1/es unknown
- 2021-10-07 MX MX2025011559A patent/MX2025011559A/es unknown
- 2021-11-08 CO CONC2021/0015054A patent/CO2021015054A2/es unknown
-
2025
- 2025-05-20 JP JP2025083936A patent/JP2025131625A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025131625A5 (enExample) | ||
| JP4108980B2 (ja) | 持続放出ラノラジン製剤 | |
| JP4852423B2 (ja) | 固体の経口投与可能な医薬組成物の製造方法 | |
| JP5660544B2 (ja) | 安定性が向上したアムロジピン及びロサルタンを含む固形薬剤的組成物 | |
| JP5898770B2 (ja) | 心血管疾患の治療方法 | |
| JP2008069159A5 (enExample) | ||
| JP5911969B2 (ja) | 心臓血管障害の治療方法 | |
| JP2011522876A (ja) | 永続性心房細動を予防するためのドロネダロン | |
| JP2009510138A5 (enExample) | ||
| BRPI0518266B1 (pt) | medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular | |
| JP2010516702A5 (enExample) | ||
| CN102149377A (zh) | 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途 | |
| TWI592154B (zh) | Allisartan-based solid dispersions and pharmaceutical compositions containing the solid dispersions | |
| WO2010010138A1 (en) | Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease | |
| JPH10513186A (ja) | Ｈｉｖプロテアーゼ阻害剤インジナビル及び逆転写酵素阻害剤３ｔｃを必要に応じてａｚｔ、ｄｄｉ、又はｄｄｃと共に用いるｈｉｖ感染の組合せ治療 | |
| JPWO2020178767A5 (enExample) | ||
| JP2008512538A5 (enExample) | ||
| RU2756452C1 (ru) | Фармацевтический препарат | |
| JP2008524228A5 (enExample) | ||
| Bourassa | Haemodynamic and electrophysiologic effects of diltiazem | |
| EP2386300A1 (en) | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality in patients having a first recurrence of atrial fibrillation or atrial flutter | |
| VERDECCHI et al. | Increased exercise tolerance and reduced electrocardiographic ischaemia 3 and 12 hours after oral felodipine in effort angina | |
| US10016417B2 (en) | Extended release formulation of a direct thrombin inhibitor | |
| JP2019014712A (ja) | 安定なダビガトラン製剤 | |
| Rettig et al. | Comparison of dihydropyridine and phenylalkylamine calcium antagonists in patients with coronary heart disease |